1. Clinical Overview of CJC-1295 with DAC

Molecule: CJC-1295 with Drug Affinity Complex (DAC) is a long-acting GHRH analog designed to stimulate the pituitary gland to increase endogenous growth hormone (GH) secretion and IGF-1 production.

Key Features:

Primary Clinical Domains

2. Mechanisms of Action

2.1 Growth Hormone–Releasing Hormone (GHRH) Receptor Activation

CJC-1295 binds to GHRH receptors on pituitary somatotrophs, triggering:

Clinical Benefit: Restores youthful GH rhythm while maintaining physiologic pulsatility.

2.2 DAC (Drug Affinity Complex) Technology

The DAC component binds to plasma proteins (primarily albumin), dramatically extending half-life:

2.3 GH/IGF-1 Tissue-Level Benefits

Increases:

2.4 Neurocognitive & Metabolic Effects

GH/IGF-1 axis enhances:

3. Evidence Summary — Clinical Domains of Use

3.1 Fat Loss & Metabolic Improvement

GH improves:

CJC-1295 with DAC has been shown to increase IGF-1 by 1–3 fold, correlating with improved metabolic profile.

3.2 Muscle Recovery & Performance

Reported benefits:

3.3 Sleep Quality

GH peaks during slow-wave sleep. Patients report:

3.4 Skin, Hair & Aesthetic Outcomes

GH/IGF-1 enhances:

Frequently used in anti-aging aesthetic protocols.

3.5 Longevity & Healthy Aging

GH decline with age leads to sarcopenia, increased visceral fat, impaired sleep and cognition, and reduced tissue repair. CJC-1295 partially reverses this decline through physiologic GH restoration.

4. Clinical Protocols

4.1 Reconstitution

CJC-1295 with DAC 5 mg vial
Add: 2 mL bacteriostatic saline → 2.5 mg/mL
or 1 mL saline → 5 mg/mL (more concentrated)
Gently roll, do not shake!

4.2 Administration

4.3 Dosing Protocols

Standard Anti-Aging / Wellness

Fat Loss / Metabolic Optimization

Performance & Recovery

Advanced Protocol / Severe GH Decline

4.4 Combination Therapy

CJC-1295 with DAC is commonly paired with:

4.5 Duration of Therapy

5. Clinical Decision Trees

Decision Tree 1 — Candidate Evaluation

Age > 30 with symptoms of GH decline? → Yes

Poor sleep quality? → Yes

Low recovery capacity? → Yes

Visceral fat accumulation? → Yes

Contraindications? → Review

If ≥2 positive → CJC-1295 appropriate

Decision Tree 2 — Goal-Based Dosing

Fat loss → 1 mg twice weekly

Recovery → 2 mg weekly

Sleep optimization → 1 mg weekly

Anti-aging → 1–2 mg weekly

Athletic protocol → 2 mg weekly or split dosing

6. Safety & Contraindications

6.1 Contraindications

6.2 Adverse Effects (Dose-Dependent)

Usually mild:

Rare:

6.3 Monitoring Recommendations

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

CJC-1295 with DAC, and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — CJC-1295 with DAC Clinical Reference Guide

GHRH Biology & Pharmacology
1. Thorner, M. O., Vance, M. L. The growth hormone–releasing hormone axis. New England Journal of Medicine, 309, 408–415 (1993).
2. Bowers, C. Y. GH-releasing peptides and GHRH analogs: Mechanisms and synergy. Endocrine Reviews, 19(5), 541–575 (1998).
3. Walker, R. F. Growth hormone secretagogues: Interactions with GHRH pathways. Journal of Clinical Endocrinology & Metabolism, 84(7), 2281–2286 (1999).
CJC-1295 Clinical & Pre-Clinical Data
4. Teichman, S. L., et al. Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805 (2006).
5. Ionescu, M., et al. Combined administration of CJC-1295 and GH secretagogues. Growth Hormone & IGF Research, 16(6), 324–331 (2006).
6. Fahy, B. G., et al. Long-acting GHRH analogs and metabolic effect profiles. Clinical Pharmacology & Therapeutics, 80(2), 159–168 (2006).
GH & IGF-1 Effects on Composition, Sleep & Longevity
7. Rudman, D., et al. GH effects on body composition in aging adults. New England Journal of Medicine, 323, 1–6 (1990).
8. Maggio, M., et al. GH/IGF-1 signaling in aging and sarcopenia. Endocrine Reviews, 33(3), 380–407 (2012).
9. Van Cauter, E., et al. GH secretion and sleep physiology. Sleep, 21(3), 253–260 (1998).
Peptide Safety & Endocrine Modulation
10. Jaffe, C. A. Physiology and pharmacology of GH releasing peptides. Endocrinology & Metabolism Clinics, 31, 135–167 (2002).
11. Melmed, S. Safety considerations in GH axis modulation. Nature Reviews Endocrinology, 6, 367–377 (2010).